Skip to content

Contrast-enhanced harmonic endoscopic ultrasonography vs contrast-enhanced harmonic ultrasonography for diagnosing gallbladder diseases: A prospective study

Contrast-enhanced harmonic endoscopic ultrasonography vs contrast-enhanced harmonic ultrasonography for diagnosing gallbladder diseases: A prospective study - Contrast-enhanced harmonic endoscopic ultrasonography vs contrast-enhanced harmonic ultrasonography for gallbladder diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017801
Enrollment
30
Registered
2015-06-04
Start date
2015-06-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallbladder neoplastic lesion

Interventions

use of ultrasonography enhance agent Sonazoid (Daiichisankyo, Tokyo, Japan)

Sponsors

Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Men and Women older than twenty years old. 2. Patients observed neoplastic lesion with major axis larger than 10 mm by CT, or B mode ultrasonography. For example, gallbladder cancer, gallbladder adenoma, adenomyomatosis, gallbladder polyps). 3. Function of major organs are good. 4. Patients who give a written concent for this study.

Exclusion criteria

Exclusion criteria: 1. very low performance status (3-4) 2. Patients who are not performed surgery or endoscopy because of serious heart failure, or serious renal failure, or cerebrovascular diseases, etc. 3. Patients who were judged incompatible by attendig doctor.

Design outcomes

Primary

MeasureTime frame
Diagnosabiligy of CH-EUS, or CH-US

Secondary

MeasureTime frame
To compare the following items between CH-EUS and CH-US, or before and after contrast enhance of EUS, or US. 1. evauation of gallbladder cancer invasion depth. 2. diagnosability To clarify diagnosable patients only by CH-US.

Countries

Japan

Contacts

Public ContactMitsuru Sugimoto

School of Medicine, Fukushima medical university Gastroenterology and Rheumatology

kita335@fmu.ac.jp024-547-1202

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026